vaccine
FDA Grants Emergency Use Authorization for Remdesivir
The FDA grants Emergency Use Authorization for remdesivir — an antiviral initially developed against Ebola — as the first treatment specifically authorized for COVID-19. Clinical trials showed it shortened hospitalization time by approximately 4 days, though early mortality benefits remained uncertain.
Sources
- T1 FDA EUA Announcement Official
- T2 NEJM Clinical Trial Major